The lack of availability, accessibility and cost of hydroxyurea, a drug used in the treatment of sickle cell anemia in Lubumbashi, is a major obstacle to improving the health status of sickle cell disease and also decreases the quality of care provided. This research aims, the study on the availability and cost of hydroxyurea used in the treatment of sickle cell anemia in Lubumbashi. Methods: This is a descriptive cross-sectional study conducted from 1 October to 30 November 2016. The data were collected through a questionnaire developed for this purpose and subject to 160 officials pharmacies and wholesale establishments (EVG) of the city of Lubumbashi. These data were analyzed from the Microsoft Excel 2013 for the calculation of the mean and standard deviation. Results: Our study showed that over 140 pharmacies surveyed, hydroxyurea was available in 14 pharmacies 10% in capsule form dosed at 500 mg, manufactured by Bristol-Myers Squibb Canada lab named "Hydrea®" which is the trademark of that laboratory and an average cost of 14535 ± 3371.05 Congolese Francs (FC) equivalent to 14.83 ± 3.44 US dollars (US $) for the box of 20 capsules 500mg. Regarding frequented EVG 20, 10 or 50% disponilisaient product at an average cost of 11063 ± 3190.60 FC representing 11.29 ± US $ 3.26 for the same box. Conclusion: Ignorance of hydroxyurea by the majority of managers (not pharmacists) pharmacies makes it virtually unavailable and the cost seems high for lack of financial means of the parents of affected children.
